chronic hepatitis B
Conditions
Interventions
experimental group:Oral tenofovir alafenamide fumarate
control group:Oral entecavir
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Those who conform to the relevant diagnostic criteria of CHB in the 2015 version of the Guidelines for the Prevention and Treatment of Chronic Hepatitis B. 2) Patients with nonalcoholic cirrhosis in accord with the diagnostic criteria of the 2018 version of the Guidelines for the Prevention and Treatment of Non-alcoholic Fatty Liver Disease. 3) those who sign informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients with liver cirrhosis. 2) Patients with severe primary diseases such as heart, liver, kidney and hematopoietic system diseases. 3) Those who have mental or cognitive impairment and are unable to cooperate with treatment. 4) Those who are allergic to drugs used in this study. 5) Those who die during treatment,pregnant or lactating women, etc. 6) Aged = 70 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbsAg quantity;HBV-DNA quantity;Weight;BMI;Blood lipids;Liver hardness value;Controlled attenuation coefficient value; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver function;Liver IR index;Insulin resistance index;Internal diameter of spleen and portal vein and thickness of spleen; | — |
Countries
China
Contacts
Public ContactYe Feng
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed